Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGT-181 in Adult Patients With Mucopolysaccharidosis I
NCT02371226Phase 1Completed
- Sponsor
- ArmaGen
- Start
- Jul 2015
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of valanafusp alpha in mucopolysaccharidosis type I (3 cohorts), sponsored by ArmaGen. Primary endpoint: Number of participants with adverse events as a measure of safety and tolerability at 8 weeks. Started Jul 2015; status: completed.
02
Drugs
valanafusp alpha
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT02371226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371226.